Simmi Singh was interviewed by as part of HIT.IQ’s leadership conversation series regarding innovators and entrepreneurs in healthcare.

A fireside chat with Mark Krymalowski, Head of the EMEA Digital Practice at Egon Zehnder, sat down with Dr. Bernd Montag, CEO of Siemens Healthineers was part of the NOAH Conference 2018.

A number of senior leaders in life sciences have elected to make the leap from big pharma to lesser-known startup or biotech companies. So what propelled these executives to make the move?

The European commission is to push for a quota for women on company boards to address the slow progress to gender equality in the senior ranks of publicly listed businesses. Previous attempts by the EU’s executive to set a 40% goal for women in the top ranks of listed companies have been blocked by Germany, the Netherlands and Sweden overs fears that Brussels was overreaching into domestic affairs. Hungary and Poland have opposed the move on ideological grounds.

Egon Zehnder Istanbul recently hosted a presentation by Cozi Namer, Healthcare Industry Development Lead at Google, based in New York. As the subject of digital revolution continues to gain momentum in the performance-focused corporate world, healthcare industry is also in a state of constant transformation.

Disruption in healthcare will continue to be profound, widespread and unpredictable, regardless of what ultimately happens with the Affordable Care Act, or the recently introduced American Health Care Act of 2017.

Health, Pharma and Leadership. Quality executives used to be the in-house police; internal affairs officers investigating production errors and mishaps and reporting them up the chain of command.

With Sarbanes-Oxley increasing the responsibilities shouldered by today’s directors, do some individuals have a seat on too many US boards, asks The Boston Globe?

Healthcare has been in a state of steady, sometimes grudging, transformation for years. What’s different today is the dramatically accelerated pace of change that has been brought on by a combination of regulatory pressures, high costs, consumer empowerment, and revolutionary technological and medical innovation.

The generics industry has entered a phase of radical transformation. Rapid globalization, continuing consolidation, and increasing business complexity have turned formerly regional players into global operations.